Search results
Results From The WOW.Com Content Network
Bristol Myers Squibb has been accused in a new lawsuit of using fraudulent patents and other illegal tactics to maintain its monopoly on blockbuster blood cancer drug Pomalyst for years after it ...
A U.S. judge on Friday refused to dismiss a $6.4 billion lawsuit accusing Bristol Myers Squibb Co of delaying its Breyanzi cancer drug to avoid payments to shareholders of the former Celgene Corp ...
Bristol-Myers Squibb (BMY) closed at $60.50 in the latest trading session, marking a -1.59% move from the prior day. Bristol-Myers Squibb (BMY) Stock Moves -1.59%: What You Should Know Skip to ...
XIV. Bristol-Myers Squibb Co. v. Superior Court of California, San Francisco County, 582 U.S. ___ (2017), was a United States Supreme Court case in which the Court held that California courts lacked personal jurisdiction over the defendant on claims brought by plaintiffs who are not California residents and did not suffer their alleged injury ...
The Bristol-Myers Squibb Company, doing business as Bristol Myers Squibb ( BMS ), is an American multinational pharmaceutical company. Headquartered in Princeton, New Jersey, [ 2] BMS is one of the world's largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations.
Bristol Myers Squibb (BMY) closed at $65.26 in the latest trading session, marking a -1.03% move from the prior day.
In the latest trading session, Bristol-Myers Squibb (BMY) closed at $49.24, marking a +1.4% move from the previous day.
In the latest trading session, Bristol Myers Squibb (BMY) closed at $62.46, marking a +0.19% move from the previous day.